Psilocybin Study Shows Early Promise for Parkinson’s Patients
Last reviewed and updated: June 24, 2026.
Key Takeaways
| Why psilocybin + PD | NOT dopamine-based; targets depression/anxiety (50% of PD patients), neuroplasticity (BDNF), and quality of life |
| Research stage | Phase 1/2 early trials; safety and mood outcomes primary focus; motor symptoms less studied |
| Drug interaction risk | MAO-B inhibitors (selegiline, rasagiline) common in PD — interaction with psilocybin raises serotonin syndrome risk; requires screening |
| Clinical access | Clinical trials at clinicaltrials.gov; Oregon service centers; Colorado personal possession — no approved PD-specific protocol |
| Realistic framing | Early-stage research; promising for non-motor symptoms; field to watch, not an established treatment |
A new clinical trial has found that psilocybin, the active compound in psychedelic mushrooms, may help ease both motor and mood symptoms in people living with Parkinson’s disease. The findings, presented at the 2024 American Academy of Neurology meeting, suggest that the psychedelic compound could offer a new pathway for symptom management in this hard-to-treat condition.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Here is a breakdown of the key findings:
| Key Takeaway | Details |
|---|---|
| Study Size | 12 patients with Parkinson’s disease |
| Treatment | Single 25 mg oral dose of psilocybin |
| Mood Improvements | 83% showed meaningful reductions in anxiety or depression |
| Motor Improvements | 75% had improved motor scores, particularly tremor and bradykinesia |
| Onset of Effects | Most patients noticed effects within 2 days |
| Duration of Benefits | Effects lasted at least 2 weeks for many participants |
| Adverse Effects | Mild and short lived, including nausea and headache |
| Next Steps | Larger trials needed to confirm safety and efficacy |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
A Fast Response with Minimal Side Effects
Participants received a single 25 mg capsule of psilocybin in a clinical setting with professional monitoring. Most reported noticeable improvements in anxiety and depression within 48 hours. Many also experienced a reduction in tremors and other movement-related symptoms that are common in Parkinson’s disease. Notably, these benefits were observed without serious side effects. Some participants experienced mild nausea or a brief headache, but the symptoms resolved quickly.
The trial, led by researchers from the Pacific Neuroscience Institute, focused on individuals who were already taking standard Parkinson’s medications. Psilocybin was used as an adjunct, not a replacement. While the results are preliminary, they open the door to a potential new class of supportive therapies.
A Shift in How We Understand Treatment
Parkinson’s disease is typically associated with motor dysfunction, but mood disorders such as anxiety and depression also affect quality of life. Traditional medications do little to address both sets of symptoms at once. Psilocybin’s ability to target both areas could shift how clinicians think about treatment strategies.
Still, the study’s small size limits broad conclusions. Larger, placebo-controlled studies will be essential before psilocybin can be considered a standard treatment option.
Yet for those living with a condition that gradually takes away mobility and independence, the possibility of an effective new tool brings hope. As research into psychedelic therapies expands, psilocybin continues to emerge as one of the most closely watched compounds in the neuroscience field.
Psilocybin and Parkinson’s: Why Researchers Are Interested and What the Evidence Shows
The rationale for studying psilocybin in Parkinson’s disease (PD) is distinct from the rationale for depression or anxiety — and understanding why researchers are interested helps contextualize what the early studies are actually testing.
Why psilocybin, why Parkinson’s? Parkinson’s disease is primarily characterized by loss of dopaminergic neurons in the substantia nigra. Current treatments focus on dopamine replacement (levodopa, dopamine agonists) but do not slow disease progression, and long-term levodopa use produces its own complications (dyskinesia, motor fluctuations). Psilocybin is not a dopamine agonist — it acts primarily at serotonin receptors (5-HT2A). The rationale for studying it in PD is not direct dopamine pathway intervention. Rather, researchers are interested in three other mechanisms: (1) neuroplasticity — psilocybin promotes BDNF (brain-derived neurotrophic factor) expression and dendritic branching, which could theoretically support neuroprotection or compensation in PD; (2) depression and anxiety in PD — up to 50% of Parkinson’s patients experience depression, and psilocybin’s anti-depressant effects in cancer patients and treatment-resistant depression are well-documented; (3) cognitive and quality-of-life outcomes — PD frequently produces cognitive decline, and psilocybin’s effects on neuroplasticity and default mode network function may have relevance.
Where the research is now. Research on psilocybin specifically for Parkinson’s is at early stage — small open-label or Phase 1/2 trials examining safety, tolerability, and preliminary efficacy signals. This is appropriate given PD’s complexity: patients are often older, on multiple medications (many of which interact with serotonergic compounds), and have motor symptoms that complicate the supervised psilocybin session format. A key safety consideration is serotonin syndrome risk in PD patients on selegiline or rasagiline (MAO-B inhibitors), which are common PD medications — these interactions require careful screening. The early results on depression and anxiety in PD patients have been encouraging, consistent with findings in other patient populations. Motor symptom effects are less studied and less clear. This is a field to watch, not one with established clinical recommendations.
Frequently Asked Questions
How might psilocybin help Parkinson’s disease?
Researchers are exploring three mechanisms: (1) Depression and anxiety — up to 50% of PD patients experience depression; psilocybin’s anti-depressant effects are the most established application and most directly relevant to PD co-morbidities; (2) Neuroplasticity — psilocybin promotes BDNF expression and dendritic branching, which could theoretically support neural compensation or neuroprotection; (3) Quality of life — psilocybin may improve overall wellbeing and cognitive flexibility. Psilocybin is NOT a dopamine agonist and does not work through the same mechanism as standard PD medications — it would be a complementary approach targeting non-motor symptoms, not the primary dopaminergic pathway.
Is psilocybin safe for Parkinson’s patients?
Safety in PD patients is being studied carefully and is more complex than in healthy adults. Key concerns: (1) MAO-B inhibitor interactions — selegiline (Eldepryl) and rasagiline (Azilect) are common PD medications that inhibit monoamine oxidase-B; combining with serotonergic substances like psilocybin raises serotonin syndrome risk; (2) Levodopa interactions — the interaction between psilocybin and levodopa is not fully characterized; (3) Physical setting considerations — PD motor symptoms (tremor, rigidity, dyskinesia) require careful session management; (4) Older patient population — PD typically affects people 60+, who may have different pharmacokinetics and more comorbidities. Current clinical trials on psilocybin in PD use careful screening criteria and should be the route for PD patients interested in psilocybin access.
What treatments currently exist for Parkinson’s disease?
Current Parkinson’s treatments manage symptoms but do not halt disease progression. The primary treatments: (1) Levodopa/carbidopa — the gold standard; replenishes dopamine; highly effective but causes dyskinesia and motor fluctuations with long-term use; (2) Dopamine agonists (pramipexole, ropinirole) — activate dopamine receptors directly; used early in disease or alongside levodopa; (3) MAO-B inhibitors (selegiline, rasagiline) — slow dopamine breakdown; neuroprotective effects under study; (4) Deep brain stimulation (DBS) — surgical option for advanced PD with motor fluctuations; effective but invasive; (5) Anticholinergics, amantadine — supplemental medications for specific symptoms. Research into disease-modifying therapies (alpha-synuclein targeting, neuroinflammation) is ongoing. Psilocybin research is exploring non-motor symptoms (depression, anxiety, quality of life) as a complementary area.
Are there clinical trials for psilocybin in Parkinson’s?
Yes, though in early stages. Clinical trials on psilocybin in Parkinson’s disease can be found at clinicaltrials.gov by searching “psilocybin Parkinson’s.” Most current trials are Phase 1 or 2, primarily examining safety, tolerability, and preliminary signals on mood and quality of life rather than motor symptoms. Eligibility criteria typically exclude patients on MAO inhibitors and may have other specific requirements. Participation in a clinical trial is currently the most accessible legal route for PD patients interested in psilocybin — outside Oregon (licensed service centers) or Colorado (personal possession, no licensed centers yet for supervised sessions).
